TABLE 4.
Poisson regression models for 30-day mortality by pharmacodynamic parameter among MRSA-B patients
| Model and characteristic | Adjusted risk ratio (95% CI) | P value |
|---|---|---|
| Model 1 | ||
| VAN AUC24/MBC < 176 | 3.68 (1.17–11.56) | 0.025 |
| Age ≥85 yr | 4.24 (1.75–10.23) | 0.001 |
| Malignancy | 5.62 (2.31–13.65) | <0.001 |
| PBS ≥ 4 | 3.63 (1.48–8.67) | 0.005 |
| Cirrhosis | 6.33 (0.60–67.38) | 0.120 |
| Model 2 | ||
| VAN AUC24/MICBMD < 334 | 5.12 (0.85–30.67) | 0.074 |
| Malignancy | 3.70 (1.25–10.97) | 0.019 |
| MRSA pneumonia | 3.56 (1.13–11.26) | 0.031 |
| Cirrhosis | 9.88 (0.72–34.79) | 0.086 |
| Model 3 | ||
| VAN AUC/MICBMD < 400 | 1.95 (0.92–4.15) | 0.084 |
| Malignancy | 3.89 (1.31–11.53) | 0.014 |
| MRSA pneumonia | 3.59 (1.16–11.11) | 0.026 |
| Cirrhosis | 3.73 (0.39–36.07) | 0.255 |